The guideline-recommended treatment for eligible patients with acute ischemic stroke is thrombolytic therapy using recombinant tissue-type plasminogen activator (rt-PA) to dissolve blood clots, which was approved by the U.S. Food and Drug Administration in 1996 for intravenous use within 3 h of stroke [4,5]. This evidence concerns the gene PLAT and stroke disorder.